Compare LNG & GEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LNG | GEHC |
|---|---|---|
| Founded | 1983 | 1892 |
| Country | United States | United States |
| Employees | 1714 | N/A |
| Industry | Oil/Gas Transmission | Computer Software: Prepackaged Software |
| Sector | Utilities | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.5B | 38.9B |
| IPO Year | 1997 | N/A |
| Metric | LNG | GEHC |
|---|---|---|
| Price | $206.97 | $81.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 11 |
| Target Price | ★ $264.69 | $88.27 |
| AVG Volume (30 Days) | 1.8M | ★ 2.9M |
| Earning Date | 02-19-2026 | 02-04-2026 |
| Dividend Yield | ★ 1.07% | 0.17% |
| EPS Growth | 14.15 | ★ 32.35 |
| EPS | ★ 17.92 | 4.83 |
| Revenue | $18,937,000,000.00 | ★ $20,246,000,000.00 |
| Revenue This Year | $30.79 | $6.33 |
| Revenue Next Year | $13.52 | $4.32 |
| P/E Ratio | ★ $11.53 | $16.92 |
| Revenue Growth | ★ 21.55 | 3.51 |
| 52 Week Low | $186.20 | $57.65 |
| 52 Week High | $257.65 | $94.80 |
| Indicator | LNG | GEHC |
|---|---|---|
| Relative Strength Index (RSI) | 66.58 | 43.84 |
| Support Level | $192.01 | $84.59 |
| Resistance Level | $199.32 | $87.60 |
| Average True Range (ATR) | 4.94 | 2.20 |
| MACD | 1.85 | -0.55 |
| Stochastic Oscillator | 92.03 | 4.64 |
Cheniere Energy is a liquified natural gas, or LNG, producer with two facilities in Corpus Christi, Texas and Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed and variable fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. A subsidiary, Cheniere Energy Partners, owns the Sabine Pass facility and trades as a master limited partnership.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 12%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).